Abstract
Summary
The global Recombinant Monoclonal Antibody market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world Recombinant Monoclonal Antibody sales in 2023, providing a comprehensive analysis by region and market sector of projected Recombinant Monoclonal Antibody sales for 2024 through 2030. With Recombinant Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Monoclonal Antibody industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Monoclonal Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Monoclonal Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Monoclonal Antibody.
United States market for Recombinant Monoclonal Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Recombinant Monoclonal Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Recombinant Monoclonal Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Recombinant Monoclonal Antibody players cover Abcam, Boster Bio, Evitria, Novus Biologicals and ACROBiosystems, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Monoclonal Antibody market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Humanized Antibodies
Small Molecule Antibody
Other
Segmentation by application
Immunohistochemistry
Western Blot
Immunofluorescence
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abcam
Boster Bio
Evitria
Novus Biologicals
ACROBiosystems
Abyntek Biopharma
Sino Biological
Enzo Life Sciences
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Monoclonal Antibody market?
What factors are driving Recombinant Monoclonal Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Monoclonal Antibody market opportunities vary by end market size?
How does Recombinant Monoclonal Antibody break out type, application?
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world Recombinant Monoclonal Antibody sales in 2023, providing a comprehensive analysis by region and market sector of projected Recombinant Monoclonal Antibody sales for 2024 through 2030. With Recombinant Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Monoclonal Antibody industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Monoclonal Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Monoclonal Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Monoclonal Antibody.
United States market for Recombinant Monoclonal Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Recombinant Monoclonal Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Recombinant Monoclonal Antibody is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Recombinant Monoclonal Antibody players cover Abcam, Boster Bio, Evitria, Novus Biologicals and ACROBiosystems, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Monoclonal Antibody market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Humanized Antibodies
Small Molecule Antibody
Other
Segmentation by application
Immunohistochemistry
Western Blot
Immunofluorescence
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abcam
Boster Bio
Evitria
Novus Biologicals
ACROBiosystems
Abyntek Biopharma
Sino Biological
Enzo Life Sciences
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Monoclonal Antibody market?
What factors are driving Recombinant Monoclonal Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Monoclonal Antibody market opportunities vary by end market size?
How does Recombinant Monoclonal Antibody break out type, application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Monoclonal Antibody Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant Monoclonal Antibody by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant Monoclonal Antibody by Country/Region, 2019, 2023 & 2030
2.2 Recombinant Monoclonal Antibody Segment by Type
2.2.1 Humanized Antibodies
2.2.2 Small Molecule Antibody
2.2.3 Other
2.3 Recombinant Monoclonal Antibody Sales by Type
2.3.1 Global Recombinant Monoclonal Antibody Sales Market Share by Type (2019-2024)
2.3.2 Global Recombinant Monoclonal Antibody Revenue and Market Share by Type (2019-2024)
2.3.3 Global Recombinant Monoclonal Antibody Sale Price by Type (2019-2024)
2.4 Recombinant Monoclonal Antibody Segment by Application
2.4.1 Immunohistochemistry
2.4.2 Western Blot
2.4.3 Immunofluorescence
2.4.4 Other
2.5 Recombinant Monoclonal Antibody Sales by Application
2.5.1 Global Recombinant Monoclonal Antibody Sale Market Share by Application (2019-2024)
2.5.2 Global Recombinant Monoclonal Antibody Revenue and Market Share by Application (2019-2024)
2.5.3 Global Recombinant Monoclonal Antibody Sale Price by Application (2019-2024)
3 Global Recombinant Monoclonal Antibody by Company
3.1 Global Recombinant Monoclonal Antibody Breakdown Data by Company
3.1.1 Global Recombinant Monoclonal Antibody Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant Monoclonal Antibody Sales Market Share by Company (2019-2024)
3.2 Global Recombinant Monoclonal Antibody Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant Monoclonal Antibody Revenue by Company (2019-2024)
3.2.2 Global Recombinant Monoclonal Antibody Revenue Market Share by Company (2019-2024)
3.3 Global Recombinant Monoclonal Antibody Sale Price by Company
3.4 Key Manufacturers Recombinant Monoclonal Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Monoclonal Antibody Product Location Distribution
3.4.2 Players Recombinant Monoclonal Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Recombinant Monoclonal Antibody by Geographic Region
4.1 World Historic Recombinant Monoclonal Antibody Market Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant Monoclonal Antibody Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant Monoclonal Antibody Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant Monoclonal Antibody Market Size by Country/Region (2019-2024)
4.2.1 Global Recombinant Monoclonal Antibody Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant Monoclonal Antibody Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant Monoclonal Antibody Sales Growth
4.4 APAC Recombinant Monoclonal Antibody Sales Growth
4.5 Europe Recombinant Monoclonal Antibody Sales Growth
4.6 Middle East & Africa Recombinant Monoclonal Antibody Sales Growth
5 Americas
5.1 Americas Recombinant Monoclonal Antibody Sales by Country
5.1.1 Americas Recombinant Monoclonal Antibody Sales by Country (2019-2024)
5.1.2 Americas Recombinant Monoclonal Antibody Revenue by Country (2019-2024)
5.2 Americas Recombinant Monoclonal Antibody Sales by Type
5.3 Americas Recombinant Monoclonal Antibody Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Monoclonal Antibody Sales by Region
6.1.1 APAC Recombinant Monoclonal Antibody Sales by Region (2019-2024)
6.1.2 APAC Recombinant Monoclonal Antibody Revenue by Region (2019-2024)
6.2 APAC Recombinant Monoclonal Antibody Sales by Type
6.3 APAC Recombinant Monoclonal Antibody Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Monoclonal Antibody by Country
7.1.1 Europe Recombinant Monoclonal Antibody Sales by Country (2019-2024)
7.1.2 Europe Recombinant Monoclonal Antibody Revenue by Country (2019-2024)
7.2 Europe Recombinant Monoclonal Antibody Sales by Type
7.3 Europe Recombinant Monoclonal Antibody Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Monoclonal Antibody by Country
8.1.1 Middle East & Africa Recombinant Monoclonal Antibody Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant Monoclonal Antibody Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant Monoclonal Antibody Sales by Type
8.3 Middle East & Africa Recombinant Monoclonal Antibody Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Monoclonal Antibody
10.3 Manufacturing Process Analysis of Recombinant Monoclonal Antibody
10.4 Industry Chain Structure of Recombinant Monoclonal Antibody
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Monoclonal Antibody Distributors
11.3 Recombinant Monoclonal Antibody Customer
12 World Forecast Review for Recombinant Monoclonal Antibody by Geographic Region
12.1 Global Recombinant Monoclonal Antibody Market Size Forecast by Region
12.1.1 Global Recombinant Monoclonal Antibody Forecast by Region (2025-2030)
12.1.2 Global Recombinant Monoclonal Antibody Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Monoclonal Antibody Forecast by Type
12.7 Global Recombinant Monoclonal Antibody Forecast by Application
13 Key Players Analysis
13.1 Abcam
13.1.1 Abcam Company Information
13.1.2 Abcam Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.1.3 Abcam Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Abcam Main Business Overview
13.1.5 Abcam Latest Developments
13.2 Boster Bio
13.2.1 Boster Bio Company Information
13.2.2 Boster Bio Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.2.3 Boster Bio Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Boster Bio Main Business Overview
13.2.5 Boster Bio Latest Developments
13.3 Evitria
13.3.1 Evitria Company Information
13.3.2 Evitria Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.3.3 Evitria Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Evitria Main Business Overview
13.3.5 Evitria Latest Developments
13.4 Novus Biologicals
13.4.1 Novus Biologicals Company Information
13.4.2 Novus Biologicals Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.4.3 Novus Biologicals Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novus Biologicals Main Business Overview
13.4.5 Novus Biologicals Latest Developments
13.5 ACROBiosystems
13.5.1 ACROBiosystems Company Information
13.5.2 ACROBiosystems Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.5.3 ACROBiosystems Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 ACROBiosystems Main Business Overview
13.5.5 ACROBiosystems Latest Developments
13.6 Abyntek Biopharma
13.6.1 Abyntek Biopharma Company Information
13.6.2 Abyntek Biopharma Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.6.3 Abyntek Biopharma Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Abyntek Biopharma Main Business Overview
13.6.5 Abyntek Biopharma Latest Developments
13.7 Sino Biological
13.7.1 Sino Biological Company Information
13.7.2 Sino Biological Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.7.3 Sino Biological Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Sino Biological Main Business Overview
13.7.5 Sino Biological Latest Developments
13.8 Enzo Life Sciences
13.8.1 Enzo Life Sciences Company Information
13.8.2 Enzo Life Sciences Recombinant Monoclonal Antibody Product Portfolios and Specifications
13.8.3 Enzo Life Sciences Recombinant Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Enzo Life Sciences Main Business Overview
13.8.5 Enzo Life Sciences Latest Developments
14 Research Findings and Conclusion